-
公开(公告)号:JPS6387981A
公开(公告)日:1988-04-19
申请号:JP23400386
申请日:1986-09-30
Applicant: AGENCY IND SCIENCE TECHN
Inventor: IWAKURA MASAHIRO , KOKUBU TOMOKUNI , FURUSAWA KIYOTAKA , TSUDA KEISHIRO
Abstract: PURPOSE:To provide a recombinant plasmid containing integrated gene of dihydrofolic acid reductase (DHFR)-leucine encephaline fused protein, stably replicable in E.coli and capable of imparting said host with trimethoprim resistance and ampicillin resistance. CONSTITUTION:Plasmid pBSDHFR1 is cut with restriction enzymes EcoRI and PstI and separated by 1% agarose gel electrophoresis to obtain a small fragment DNA. Separately, plasmid pBR322 is cut with restriction enzyme BamHI and Pst and separated by 1% agarose gel electrophoresis to obtain a large fragment DNA. The DNA of formula I and formula II are synthesized, the 5'-terminal is converted to phosphoric acid group and the product is annealed to obtain a DNA coding leucine encephaline. The above 3 kinds of DNA molecules are linked together, introduced into E.coli C600 strain and cultured. The objective recombinant DNA containing the sequence of formula III coding a DHFR-leucine encephaline fused protein can be separated from the obtained colony.
-
公开(公告)号:JPH01224391A
公开(公告)日:1989-09-07
申请号:JP4927388
申请日:1988-03-02
Applicant: AGENCY IND SCIENCE TECHN
Inventor: FURUSAWA KIYOTAKA , SAKAI TSUKASA
IPC: C07H19/067 , C07H19/167 , C07H23/00
Abstract: NEW MATERIAL:A compound of formula I [B is nucleic acid base which may be protected; R, R' are phenyl, branched alkyl or 3 or more carbon atoms.; R'' is tetrahydropyranyl residue]. EXAMPLE:2'-O-tetrahydropyranyl-3',5'-O-(di-tert.-butylsilandiyl)-uridine. USE:An intermediate of RNA-relating compounds in genetic engineering. PREPARATION:The nucleoside of formula II is silylated with a difunctional silicon compound of the formula: RR'SiX2 (X is acid residue), then allowed to react with dihydropyran.
-
公开(公告)号:JPH01144979A
公开(公告)日:1989-06-07
申请号:JP30215787
申请日:1987-11-30
Applicant: AGENCY IND SCIENCE TECHN
Inventor: IWAKURA MASAHIRO , FURUSAWA KIYOTAKA , SAKAI TSUKASA , TANAKA YOSHIO
Abstract: PURPOSE:To produce a substance containing a heterogenic product fused to a carboxy-terminal of dihydrofolic acid reductase(DHFR), in high efficiency, by modifying a plasmid pTP70-1 capable of easily utilizing a DHFR gene as a genetic marker. CONSTITUTION:A terminator region of rrnB gene (one of ribosomal RNA genes) known as an efficient terminator is introduced at the downstream side of a DHFR gene of plasmid pTP70-1 to obtain a plasmid pTP104-4 capable of efficiently producing a substance containing heterogenic product fused to the carboxy-terminal of DHFR. The plasmid has a size of 4,466 base pairs and can impart a host E.coli with trimethoprim resistance and ampicillin resistance.
-
公开(公告)号:JPH01144978A
公开(公告)日:1989-06-07
申请号:JP30215687
申请日:1987-11-30
Applicant: AGENCY IND SCIENCE TECHN
Inventor: IWAKURA MASAHIRO , KOKUBU TOMOKUNI , FURUSAWA KIYOTAKA , OHASHI SHINICHI , SAKAI TSUKASA , TANAKA YOSHIO
Abstract: PURPOSE:To produce a peptide (GRF1-29) containing the factors from the 1st to the 29th of bovine growth hormone releasing factors, by using a specific recombinant plasmid pGRE2-15. CONSTITUTION:A recombinant plasmid is prepared by linking a GRF1-29 gene to the 3'-terminal of a dihydrofolic acid reductase (DHFR) gene using a plasmid vector pTP70-1 capable of fusing a heteropeptide to a carboxy-terminal or DHFR of E.coli. The plasmid is introduced into E.coli and expressed to enable the stable production and accumulation of a fused protein containing GRF1-29 bonded to the carboxy-terminal of DHFR in E.coli.
-
公开(公告)号:JP2000053694A
公开(公告)日:2000-02-22
申请号:JP22497998
申请日:1998-08-07
Applicant: AGENCY IND SCIENCE TECHN
Inventor: FURUSAWA KIYOTAKA
Abstract: PROBLEM TO BE SOLVED: To easily produce an O-silylated hydroxy-containing cyclic ether useful as a raw material for pharmaceuticals, etc., in one-pot at a low cost dispensing with troublesome separation procedure by successively reacting a specific OH- containing cyclic ether with a bifunctional and monofunctional silicon compounds and reacting the product with hydrofluoric acid. SOLUTION: The objective compound of formula III (when Y1 or Y2 is hydroxymethylene, the OH group is converted to OSiR4R5R6) is produced by reacting (A) a compound of formula R2R3SiX12 (R2 and R3 are each an aromatic group or a >=3C branched aliphatic group; X1 is a residue of an acid other than hydrochloric acid) with (B) a compound of formula I (R1 is a substituent free from reactivity with the component A; Y1 and Y2 are each methylene, hydroxymethylene or R1-substituted methylene; (t) and (q) are each 0 or 1) e.g. a compound of formula II [B is a (protected) nucleic acid base]}, reacting with (C) a compound of formula R4R5R6SiX2 (R4 to R6 are each an aromatic group or an aliphatic group; X2 is an eliminable group) and finally reacting with (D) hydrofluoric acid in the presence of (E) a base.
-
公开(公告)号:JPH01230595A
公开(公告)日:1989-09-14
申请号:JP5717388
申请日:1988-03-10
Applicant: AGENCY IND SCIENCE TECHN
Inventor: FURUSAWA KIYOTAKA , SAKAI TSUKASA
Abstract: PURPOSE:To eliminate the title silicon group, by hydrolyzing a specific cyclic silicon derivative to cut several sites among siloxane bonds preferentially whereby local eliminating can be done highly selectively, thus the technique can be beneficially applied to biotechnology. CONSTITUTION:The cyclic silicone derivative of the formula (B is unprotected or protected nucleic acid base; R, R' are phenyl, branched alkyl of 3 or more carbon atoms; R'' is H, unprotected or protected hydroxyl) is hydrolyzed with an acid such as hydrochloric acid or an alkali such as sodium hydroxide to cut one bond in 2 siloxane bonds preferentially whereby the objective silicon group is eliminated.
-
公开(公告)号:JPS63245680A
公开(公告)日:1988-10-12
申请号:JP7937887
申请日:1987-03-31
Applicant: AGENCY IND SCIENCE TECHN
Inventor: IWAKURA MASAHIRO , KOKUBU TOMOKUNI , FURUSAWA KIYOTAKA , OHASHI SHINICHI , TSUDA KEISHIRO
Abstract: PURPOSE:To readily give a fused protein measurable enzymatic activity by making up a novel recombined plasmid pGIF1 including a gene coding fused protein from dehydrofolate reductase and somastatin to solubilize the fused protein. CONSTITUTION:The recombinant plasmid pGIF1 is stably copied in E. coli and gives the host E. coli, resistance to trimethoprim and ampicillin. In the plasmid, the gene giving trimethoprim resistance is recombined by modifying a part of the 3'-terminal of dihydrofolate reductase in Bacillus subtilis to code the fused protein with 4789 pairs of bases. The recombinant plasmid pGIF1 is introduced into E. coli C600 strain and the transformed strain is deposited as FERM P-9301.
-
公开(公告)号:JPS63102698A
公开(公告)日:1988-05-07
申请号:JP24925986
申请日:1986-10-20
Applicant: AGENCY IND SCIENCE TECHN
Inventor: IWAKURA MASAHIRO , KOKUBU TOMOKUNI , FURUSAWA KIYOTAKA , OHASHI SHINICHI , TSUDA KEISHIRO
IPC: C12N15/09 , C07K1/12 , C07K14/00 , C07K14/575 , C07K14/655 , C07K14/70 , C07K19/00 , C12N1/20 , C12N9/06 , C12N15/00 , C12P21/02 , C12R1/19
Abstract: PURPOSE:To make it possible to produce leucine enkephalin, by separating dehydrofolate reductase-leucine enkephalin fusion protein produced by E.coli integrated with a specific plasmid from the other substances in a medium, purifying and decomposing by cyanogen bromide method. CONSTITUTION:Dehydrofolate reductase-leucine enkephalin fusion protein is separated from a medium in which E.coli integrated with plasmid pBSFOLEK1 by ion exchange column chromatography and gel filtration chromatography and purified. Then the protein is decomposed by cyanogen bromide decomposition method and leucine enkephalin is separated and purified by reverse phase high performance liquid chromatography.
-
公开(公告)号:JPS63102696A
公开(公告)日:1988-05-07
申请号:JP24926086
申请日:1986-10-20
Applicant: AGENCY IND SCIENCE TECHN
Inventor: IWAKURA MASAHIRO , KOKUBU TOMOKUNI , FURUSAWA KIYOTAKA , OHASHI SHINICHI , TSUDA KEISHIRO
IPC: C12N15/09 , C07K1/16 , C07K14/575 , C07K14/655 , C07K14/70 , C07K19/00 , C12N9/06 , C12N15/00 , C12P21/00 , C12P21/02 , C12R1/19
Abstract: PURPOSE:To obtain a dihydrofolate reductase-leucine enkephalin fusion protein which is protein produced by Escherichia coli integrated with a specific plasmid and a raw material for leucine enkephalin having nonhabitual morphine-like analgesic action. CONSTITUTION:Escherichia coli integrated with plasmid pBSFOLEK1 is cultivated to produce dihydrofolate reductase-leucine enkephalin fusion protein having an amino acid sequence shown by the fig. The cell is separated from the culture solution, removed, the culture solution is subjected to ion exchange chromatography and then the aimed fusion protein is separated and purified by using dihydrofolate reductase as a standard while passing through the solution gel filtration chromatography.
-
公开(公告)号:JPH10226697A
公开(公告)日:1998-08-25
申请号:JP3380897
申请日:1997-02-18
Applicant: AGENCY IND SCIENCE TECHN
Inventor: FURUSAWA KIYOTAKA
IPC: C07H19/067 , C07H19/167 , C07H23/00
Abstract: PROBLEM TO BE SOLVED: To obtain the subject new derivative useful as an intermediate for synthesizing and modifying ribonucleic acid compounds, etc., by cyclizing a nucleotide with a bifunctional silicon compound and subsequently silylating the 2-hydroxyl group of the cyclized silyl compound with a monofunctional silicon compound. SOLUTION: A new 2'-O-silyl cyclic-silicified nucleotide derivative represented by formula I [B is a (protected) nucleic acid base; R , R are each an aromatic group, a >=3C branched aliphatic group; R to R are each an aromatic group, an aliphatic group] [e.g. 2'-O-tert-butyldimethylsilyl-3',5'-O-(di-tert-butylsilanediyl) uridine]. The compound of formula I is useful as an intermediate for synthesizing and modifying ribonucleic acid compounds, etc. The compound of formula I is obtained by silylating a nucleotide of formula II with a bifunctional silicon compound of the formula: R R SiX 2 (X is an acid residue) and further silylating the remaining 2'-hydroxyl group of the obtained cyclic compound with a monofunctional silicon compound of the formula: R R R SiX (X is a releasable group).
-
-
-
-
-
-
-
-
-